Evolocumab Safely Reduces Risk for CV Events in Chronic Kidney Disease
PCSK9 inhibition with evolocumab was safe and more effective than statin monotherapy in reducing LDL-C in stable individuals with moderate CKD and clinically evident atherosclerosis.
